Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma
- 2 September 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 137 (8), 1120-1124
- https://doi.org/10.1182/blood.2020007236
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303Journal of Clinical Oncology, 2019
- Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCLBlood, 2019
- Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System RecurrenceCurrent Treatment Options in Oncology, 2018
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trialAnnals of Oncology, 2017
- CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOPJournal of Clinical Oncology, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCLBlood, 2016
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000